MX2023013015A - Metodos de tratamiento de trastornos autoinmunitarios con proteinas de union al transcrito 7 similar a inmunoglobulina (ilt7). - Google Patents

Metodos de tratamiento de trastornos autoinmunitarios con proteinas de union al transcrito 7 similar a inmunoglobulina (ilt7).

Info

Publication number
MX2023013015A
MX2023013015A MX2023013015A MX2023013015A MX2023013015A MX 2023013015 A MX2023013015 A MX 2023013015A MX 2023013015 A MX2023013015 A MX 2023013015A MX 2023013015 A MX2023013015 A MX 2023013015A MX 2023013015 A MX2023013015 A MX 2023013015A
Authority
MX
Mexico
Prior art keywords
methods
treatment
binding proteins
autoimmune disorders
ilt7
Prior art date
Application number
MX2023013015A
Other languages
English (en)
Spanish (es)
Inventor
William Rees
Jorn Drappa
Gabor Illei
John Ratchford
Li Yan
Edward Hammond
Original Assignee
Viela Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viela Bio Inc filed Critical Viela Bio Inc
Publication of MX2023013015A publication Critical patent/MX2023013015A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
MX2023013015A 2021-05-04 2022-05-04 Metodos de tratamiento de trastornos autoinmunitarios con proteinas de union al transcrito 7 similar a inmunoglobulina (ilt7). MX2023013015A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202163183886P 2021-05-04 2021-05-04
US202163197789P 2021-06-07 2021-06-07
US202163242768P 2021-09-10 2021-09-10
US202163249953P 2021-09-29 2021-09-29
US202263326424P 2022-04-01 2022-04-01
PCT/US2022/027620 WO2022235758A1 (en) 2021-05-04 2022-05-04 Methods of treatment of autoimmune disorders using ilt7 binding proteins

Publications (1)

Publication Number Publication Date
MX2023013015A true MX2023013015A (es) 2023-11-15

Family

ID=82021082

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023013015A MX2023013015A (es) 2021-05-04 2022-05-04 Metodos de tratamiento de trastornos autoinmunitarios con proteinas de union al transcrito 7 similar a inmunoglobulina (ilt7).

Country Status (10)

Country Link
US (1) US20240287176A1 (https=)
EP (1) EP4333877A1 (https=)
JP (1) JP2024516698A (https=)
KR (1) KR20240004451A (https=)
AU (1) AU2022270101A1 (https=)
BR (1) BR112023023036A2 (https=)
CA (1) CA3217278A1 (https=)
IL (1) IL308132A (https=)
MX (1) MX2023013015A (https=)
WO (1) WO2022235758A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017231833B2 (en) 2016-03-10 2024-03-14 Viela Bio, Inc. ILT7 binding molecules and methods of using the same
AR130042A1 (es) * 2022-07-27 2024-10-30 Viela Bio Inc Formulaciones que comprenden una proteína de unión al transcripto 7 similar a inmunoglobulina (ilt7)
EP4593823A1 (en) * 2022-09-30 2025-08-06 Abbvie Inc. Methods of treating hidradenitis suppurativa
WO2024126431A1 (en) * 2022-12-12 2024-06-20 Horizon Therapeutics Ireland Dac Anti-ilt7 binding agents for the treatment and prevention of myositis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ616992A (en) * 2005-12-20 2015-07-31 Sbi Biotech Co Ltd Anti-ilt7 antibody
US20110311558A1 (en) * 2008-12-01 2011-12-22 The Board Of Regents Of The University Of Texas System Recombinant Bone Marrow Stromal Antigen-2 in the Treatment of Autoimmune Diseases
CA2772921A1 (en) * 2009-09-03 2011-03-10 Medimmune, Llc Type 1 interferon diagnostic
AU2017231833B2 (en) 2016-03-10 2024-03-14 Viela Bio, Inc. ILT7 binding molecules and methods of using the same
IL293572A (en) 2019-12-06 2022-08-01 Viela Bio Inc Treatment methods using ilt7 binding proteins

Also Published As

Publication number Publication date
BR112023023036A2 (pt) 2024-01-23
JP2024516698A (ja) 2024-04-16
WO2022235758A1 (en) 2022-11-10
EP4333877A1 (en) 2024-03-13
AU2022270101A1 (en) 2023-10-05
KR20240004451A (ko) 2024-01-11
US20240287176A1 (en) 2024-08-29
IL308132A (en) 2023-12-01
CA3217278A1 (en) 2022-11-10

Similar Documents

Publication Publication Date Title
MX2023013015A (es) Metodos de tratamiento de trastornos autoinmunitarios con proteinas de union al transcrito 7 similar a inmunoglobulina (ilt7).
Dolcetti et al. Hierarchy of immunosuppressive strength among myeloid‐derived suppressor cell subsets is determined by GM‐CSF
US20220143084A1 (en) Modified natural killer (nk) cells for immunotherapy
Han et al. Interleukin-17 enhances immunosuppression by mesenchymal stem cells
BR112022010786A2 (pt) Métodos de tratamento usando proteínas de ligação a ilt7
Neumann et al. Induction of MHC class I genes in neurons
Lu et al. E3 ubiquitin ligase tripartite motif 7 positively regulates the TLR4-mediated immune response via its E3 ligase domain in macrophages
MX2022005236A (es) Composiciones y metodos para el tratamiento de la perdida auditiva neurosensorial mediante el uso de sistemas de vectores duales de otoferlina.
WO2003090512A3 (en) Regeneration of endogenous myocardial tissue by induction of neovascularization
JP2023507118A (ja) 治療のための操作された細胞
MX2020006973A (es) Oligonucleotidos antisentido para alfa-sinucleina y usos de los mismos.
CN108603169B (zh) 来自成体干细胞的诱导型起搏细胞和浦肯野细胞
PH12021551135A1 (en) Rna encoding a protein
MX2025001237A (es) Celulas modificadas geneticamente con expresion genica reducida para mitigar el reconocimiento de celulas inmunitarias
MY203356A (en) Antisense oligonucleotides targeting alpha-synuclein and uses thereof
WO2009058970A3 (en) A novel gene therapy approach for treating the metabolic disorder obesity
CA2524619A1 (en) Novel stem cells, nucleotide sequences and proteins therefrom
US20060223749A1 (en) Inhibition of SHIP to enhance stem cell harvest and transplantation
WO2024220578A3 (en) Zinc finger protein transcription factors for repressing nav1.7 expression
CN113599522B (zh) Kdm6作为靶标在制备用于提高早期神经外胚层分化效率的药物中的应用
US20110052546A1 (en) Inhibition of SHIP to Enhance Stem Cell Harvest and Transplantation
JP7650444B2 (ja) 尿の細胞から作製される内皮および平滑筋様組織およびその使用
WO2006104609A3 (en) Isolated myeloid-like bone marrow cell populations and methods of treatment therewith
DE602005026834D1 (de) Verwendung von gilz-protein zur modulation einer antigenspezifischen immunantwort
RU2333918C2 (ru) ее3-СЕМЕЙСТВО БЕЛКОВ И СООТВЕТСТВУЮЩИЕ ДНК-ПОСЛЕДОВАТЕЛЬНОСТИ